Henan Lingrui Pharmaceutical (SHSE:600285) Seems To Use Debt Rather Sparingly

Simply Wall StMar 4 19:55 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

Henan Lingrui Pharmaceutical Acquiring 90% Stake in Yingu Pharmaceutical for 704 Million Yuan

MT NewswiresJan 28 02:02 ET

Henan Lingrui Pharmaceutical (600285.SH): plans to acquire 90% equity of Silver Valley Pharmaceutical.

Gelonghui, January 27: Henan Lingrui Pharmaceutical (600285.SH) announced that the company intends to purchase 90% of the equity of Yinggu Pharmaceutical Co., Ltd. (hereinafter referred to as "Yinggu Pharmaceutical" or "symbol company") with its own funds, at a transaction price of 703.908 million yuan. Upon completion of this transaction, Yinggu Pharmaceutical will become a subsidiary controlled by the company and included in the consolidated financial statements of the company. After this acquisition, the company or a designated third party has the right to issue an exercise notice during the period from May 1 to May 31, 2027, according to the audited financial statements of the company for 2024 to 2026 under the consolidated scope.

Gelonghui FinanceJan 27 03:05 ET

Henan Lingrui Pharmaceutical (600285.SH): The employee stock ownership plan stock sales were completed in 2021.

Gelonghui, January 22丨 Henan Lingrui Pharmaceutical (600285.SH) announced that as of now, the company's stocks held under the 2021 employee stock ownership plan have been entirely sold through the secondary market. During the implementation of the employee stock ownership plan, the company strictly adhered to market trading rules and complied with the regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange regarding the prohibition of trading stocks during sensitive periods, and there were no circumstances of trading using inside information.

Gelonghui FinanceJan 22 02:38 ET

Investors in Henan Lingrui Pharmaceutical (SHSE:600285) Have Seen Strong Returns of 146% Over the Past Five Years

Simply Wall StJan 7 19:20 ET